Research and Markets: This Pharmaceutical Market Report on the USA Forecasts Difficult Times for the Industry but Increase

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "The Pharmaceutical Market: USA" report to their offering.

The effect of the healthcare reform will be difficult to measure but pharmaceutical sales are expected to be boosted in the long-term. R&D investments are large but growth has slowed down. Around 85.0% of the USA's pharmaceutical requirements are domestically manufactured. A number of companies have made significant cutbacks, making reductions to sales forces. There have been a number of plant closures and scaling back of investment plans. For companies traditionally reliant on chemical drugs, there is an increasing interest in moving into the biologic field. This is seen as more lucrative as it has greater scope for the development of innovative products and is less susceptible to generic competition. With their acquisitions in 2009, Pfizer and Merck have diversified and entered the biologic sector, whilst Roche has specialised in biologics and diagnostics.

The OTC sector is expected to increase by a low CAGR between 2010 and 2015. Nevertheless, the sector is attractive and market concentration continues. In March 2010, sanofi-aventis completed the acquisition of Chattem. The transaction has created the world's fifth-largest consumer healthcare company. The modern generic sector is shaped by the Hatch Waxman legislation of 1984. As a result, generics are widely-used and well-accepted in the USA. This is because generics are usually far cheaper than branded drugs, with the advent of generic competition leading to rapid price falls. The sector is expected to increase by a moderate CAGR between 2010 and 2015. The leading player is the Israeli company Teva Pharmaceuticals, followed by Sandoz, Mylan and Watson; Sandoz announced the acquisition of Oriel Therapeutics in April 2010 whilst Watson completed the acquisition of Arrow in December 2009. Nevertheless, there are still a large number of small generic players, therefore there is room for further acquisitions and mergers.

In June 2010, the US FDA revealed the first steps it is taking to implement the biosimilar pathway which was passed by Congress in March 2010, as part of the healthcare reform. The Act amends section 351 of the Public Health Service Act (PHSA) to allow for the application of a biologic product as biosimilar or interchangeable. Brand-name producers are the winners, as biosimilar competition has been restricted by implementing a 12-year data exclusivity period; this is similar to the 11-year term established in Europe. Pfizer, via its Established Products Business Unit, plans to enter the biosimilar market within five years. Recent developments in the biologic/biosimilar market include the Talecris/Grifols merger, the Celgene/Abraxis merger, Watsons biosimilar product development agreement with Itero, Mercks acquisition of Millipore, sanofi-aventis acquisition of TargeGen, Abbotts acquisition of Facet, Astellas extended tender offer to acquire OSI, and Celgenes acquisition of Gloucester Pharmaceuticals.

These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

  • Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
  • Specialised intelligence on OTCs, generics, biologics and biosimilars.
  • Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
  • A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
  • The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

Key Topics Covered:

  • Highly Detailed Report Content
  • Executive Summary
  • Macroenvironment
  • Epidemiology
  • Healthcare
  • Regulatory Affairs
  • Pricing & Reimbursement
  • Distribution Channels
  • Market Analysis
  • Competition
  • Otc Pharmaceuticals
  • Generic Pharmaceuticals
  • Biologics & Biosimilars
  • Opportunities & Challenges
  • Directory
  • Methodology & Sources

For more information visit

Source: Espicom Business Intelligence Ltd


Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Pharmaceutical